Losmapimod in COPD patients stratified by fibrinogen (EVOLUTION)
Research type
Research Study
Full title
An Evaluation of Losmapimod in patients with Chronic Obstructive Pulmonary Disease (COPD) with systemic inflammation stratified using fibrinogen (EVOLUTION)
IRAS ID
91383
Contact name
Ian B Wilkinson
Eudract number
2011-004936-75
Clinicaltrials.gov Identifier
Research summary
The main purpose of this trial is to determine the effect of Losmapimod on blood vessels in patients with COPD. Although COPD is a lung disease, it is also associated with an increased risk of heart attack and stroke. It is believed that this is a result of inflammation within the body, which damages the lining (endothelium) and walls of blood vessels. These changes can promote the development of fatty deposits within the walls of arteries (atherosclerosis) which can rupture and block arteries causing damage. GSK will be providing the IMP & Placebo. They will also be responsible for accumulating the safety information from SAE forms for inclusion in the DSUR.
REC name
East of England - Cambridge South Research Ethics Committee
REC reference
12/EE/0135
Date of REC Opinion
29 May 2012
REC opinion
Further Information Favourable Opinion